or
Remember me
Back
In addition, the company’s clinical development, manufacturing and commercial capabilities make Pfizer “a very attractive partner across a variety of deal arrangements,” said Pfizer's CEO Albert Bourla.
Pfizer these days has been slimming down while being relatively quiet on the acquisition front with small purchases. Pfizer did just buy Arena Pharmaceuticals for $6.7 billion to get its hands on an S1P modulator for inflammatory diseases, and it absorbed Immuno-oncology firm Trillium Therapeutics for $2.2 billion last year. Just last week, Pfizer unveiled a $525 million deal to buy respiratory syncytial virus specialist ReViral.
A daily snapshot of everything from market open to close.